Research article

Musculoskeletal symptoms in patients with long COVID: A cross-sectional study on Iranian patients

Mohaddeseh Azadvaria,b, Afarin Haghparsastc, Amin Nakhostin-Ansaric,d, Seyede Zahra Emami Razavib,*, Maryam Hosseini

a Department of Physical Medicine and Rehabilitation, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
b Department of Physical Medicine and Rehabilitation, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
c Sports Medicine Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
d Neuromusculoskeletal Research Center, Iran University of Medical Sciences, Tehran, Iran

ARTICLE INFO

Background and objectives: Latest studies have revealed that an increasing number of Corona Virus Disease of 2019 (COVID-19) patients may continue to feel symptoms after the acute phase. This study aimed to evaluate the prevalence of musculoskeletal symptoms after the acute phase of COVID-19 and its associated factors.

Methods: We designed a cross-sectional study from January 2021 to April 2021. An online questionnaire was designed and sent to patients who had recovered from COVID-19. The questionnaire contained questions on participants’ demographic characteristics, COVID-19 course at its acute phase, and musculoskeletal symptoms after recovering from COVID-19. Musculoskeletal symptoms associations with patients’ characteristic and COVID-19 course was evaluated.

Result: 239 patients, including 72 (30.1%) males and 167 (69.9%) females with a mean age of 37.96 years (SD = 11.19), were included in the study. 98.74% of our patients had experienced at least one musculoskeletal symptom after recovering from COVID-19, and the most common symptom was fatigue, as 91.2% of participants experienced this symptom, followed by myalgia, headache, and low back pain. High BMI, hospitalization, and ICU admission were associated with a higher risk of musculoskeletal symptoms.

Conclusion: This study indicated a high prevalence of persistent musculoskeletal symptoms among patients who recovered from COVID-19. Modifiable factors, such as BMI, can be targeted to reduce the prevalence of musculoskeletal symptoms in COVID-19 survivors and reduce its burden.

1. Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new coronavirus responsible for Corona Virus Disease of 2019 (COVID-19). COVID-19 is a syndemic of SARS-CoV-2 and non-communicable diseases affecting population groups [1]. COVID-19, caused by SARS-CoV-2, can range from asymptomatic infection to minimal symptoms to severe pulmonary involvement [2]. Different diagnostic tools have been developed for diagnosing COVID-19 infection like Polymerase Chain Reaction (PCR), Chest Computed Tomography-scan (CT-scan), and anti-viral antibody (Ab), but for a vast majority of patients, the diagnoses are made based on symptoms [2]. The SARS-CoV-2 involves different organs that result in various manifestations. Latest reviews on signs and symptoms found that COVID-19 may have respiratory (cough, dyspnea, chest pain), constitutional (fever, fatigue, chills), musculoskeletal (myalgia, arthralgia), gastrointestinal (diarrhea, abdominal pain), or neurological (confusion, headache) manifestations [3]. In more serious conditions with pulmonary involvement, respiratory symptoms are dominant [2].

Patients may continue feeling the symptoms even after the acute phase, called long-haulers [4], and this condition is referred to as long COVID. About 34% of non-hospitalized and 54% of hospitalized patients may experience symptoms after the acute phase of COVID-19 [5]. The long COVID term is used to describe the symptoms lasting more than four weeks since diagnosis without any other explanation [3, 6], although there is no consensus on its definition yet [7]. The exact mechanism of long COVID is unknown [8]. Incidence of long COVID is higher in patients with comorbidities such as cardiovascular and respiratory diseases.
or severe COVID-19 infection [4, 9]. Also, older ages and a history of psychological issues are associated with a higher risk of developing long COVID [9, 10]. Long COVID signs and symptoms are similar to acute COVID-19 infection [11, 12] and are like post-infection syndrome reported following the SARS coronavirus infection and the Middle East Respiratory Syndrome (MERS) 2012 [13]. The most common symptom of long COVID is fatigue [14, 15]; however, dyspnea, cough, chest pain, myalgia, headache, joint pain, altered taste and smell, diarrhea, and sleep disturbances are commonly reported [6, 16, 17].

Musculoskeletal symptoms are frequently reported in the acute and post-acute phases of COVID-19 [14,18,19]. The reported prevalence of fatigue, arthralgia, and myalgia during the acute phase varies between studies [20, 21]. Myalgia is usually seen in viral infections due to cytokine release, and viral arthralgia has been observed in hepatitis B and parvovirus B19 viremias [21]. However, limited data are available about their incidence after the acute phase of COVID-19. One of the main characteristics of long COVID is chronic fatigue syndrome [22]. Kasraei et al. found that 72% of hospitalized COVID-19 patients feel one or more rheumatic or musculoskeletal symptoms one month after discharge, and 44% experience fatigue [23].

As COVID-19 has infected millions of people around the world [8], the number of emerging long-COVID patients is rising, which increases the international burden of the disease [6]. However, few studies have focused on the long COVID, and most studies have evaluated patients in the acute phase of COVID-19 [23,24,25]. Also, limited information is available about musculoskeletal discomforts in patients with long COVID. In this study, we aimed to evaluate the prevalence of different musculoskeletal symptoms and their associated factors in patients with long COVID. We hypothesized that considering the inflammatory response to COVID-19, the prevalence of musculoskeletal symptoms in patients who had recovered from COVID-19 might be high. Also, we aimed to determine the factors associated with a higher risk of musculoskeletal symptoms in patients with the long-COVID syndrome.

2. Materials & methods

2.1. Design

We designed a cross-sectional study to evaluate the prevalence of post-COVID musculoskeletal symptoms. We conducted the study from January 2021 to April 2021. The ethics committee of the Tehran University of Medical Sciences approved the study protocol (Ethics code: IR.TUMS.IKHC.REC.1399.448).

2.2. Participants

Patients who had recovered from COVID-19 infection were included in the study. Inclusion criteria were: 1) diagnosis of COVID-19 by a physician based on signs and symptoms, imaging, PCR, or Ab, 2) ability to read and write in Persian 3) an at least one-month interval from the disease onset. Patients with musculoskeletal symptoms before contracting COVID-19 were excluded from the study as we wanted to evaluate the new-onset symptoms.

We used convenience sampling to recruit the subjects. We created an online questionnaire using Google form and invited the patients who recovered from COVID-19 to participate in the study. First, we identified the individuals who had been visited in outpatient clinics and those hospitalized due to COVID-19 from January 2021 to April 2021 using Sina hospital records. After that, we sent them a message explaining the study's aims and objectives and invited them to participate in the study. Individuals interested in participating in the study were asked to open the link to the online questionnaire included in the message. There was a question in the online questionnaire on the participants' consent to participate in the study.

2.3. Questionnaire

The questionnaire contained questions on demographic characteristics, past medical history, the time elapsed since the onset of COVID-19 symptoms, and the COVID-19 diagnosis method. There were also questions on the COVID-19 course at its acute phase, including intubation, hospitalization, ICU admission, and lost days due to COVID-19. Lost days due to COVID-19 were defined as the days the patients needed to rest after the onset of COVID-19 symptoms and could not do their normal activities. Musculoskeletal symptoms, including fatigue, headache, arthralgia, myalgia, neck pain, back pain, hip pain, and leg pain, and their durations were also evaluated [3].

2.4. Statistical analysis

All analyses were performed using IBM SPSS version 24. We calculated mean and standard deviation (SD) for continuous variables and number and percentage for categorical variables. We used the Chi-square test to compare the categorical variables in patients with and without musculoskeletal symptoms. We used the Kolmogorov-Smirnov test to determine whether the continuous variables are distributed normally or not. We used parametric tests, such as independent T-test, to compare the variables with normal distribution in patients with and without musculoskeletal symptoms. To compare variables that did not have a normal distribution, we used non-parametric tests, such as Mann-Whitney and Kruskal-Wallis tests, to compare patients with and without musculoskeletal symptoms. P-value ≤ 0.05 was considered statistically significant.

3. Results

Two hundred thirty-nine individuals with a mean age of 37.96 years (SD = 11.19) completed the questionnaire, including 72 men (30.1%). Forty-one patients (17.2%) had underlying diseases, of whom 10 (4.2%) had diabetes, and 7 (2.9%) had hypertension. Among the 23 patients who were hospitalized due to COVID-19, nine (39.1%) were admitted to ICU. Three (1.3%) participants had an intubation history. The mean of days lost due to COVID-19 was 18.19 days (SD = 13.89). Fatigue (91.2%), myalgia (80.3%), and headache (62.3%) were the most common symptoms among the participants. The basic and demographic characteristics of participants are shown in Table 1.

The associations between musculoskeletal symptoms of COVID-19 and other variables are shown in Tables 2 and 3. History of underlying disease was associated with persistence of fatigue for a longer period (P = 0.007). Hospitalization due to COVID-19 was associated with a longer period of arthralgia (P = 0.009), hip pain (P = 0.001), bedridden due to fatigue (P < 0.001), bedridden due to pain (P = 0.024), and exertional dyspnea (P = 0.003). Patients who were admitted to ICU reported low back pain (P = 0.020), bedridden due to fatigue (P = 0.000), and bedridden due to pain (P = 0.003) for longer periods. The female gender

2

| Table 1. Basic and demographic characteristics of participants. |
|-----------------|------------------|
| Variable        | Number (%)       |
| Gender          |                  |
| Female          | 167 (69.9%)      |
| Male            | 72 (30.1%)       |
| Presence of underlying disease | 61 (72.2%) |
| Hospitalization | 23 (6.6%)        |
| ICU admission   | 10 (4.2%)        |
| Intubation      | 3 (1.3%)         |
| Occupation      |                  |
| Unemployed      | 71 (29.7%)       |
| Healthcare worker | 46 (19.2%) |
| Other           | 122 (51.0%)      |
| Diagnosis       |                  |
| Definite        | 149 (62.3%)      |
| Indefinite      | 90 (37.7%)       |
Table 2. Associations between musculoskeletal symptoms and demographic characteristics and COVID-19 course in participants.

| Symptom          | Gender          | Presence of underlying disease | Hospitalization | ICU admission | Occupation |
|------------------|-----------------|-------------------------------|-----------------|--------------|------------|
|                  | Male            | Female                        | Yes  | No | P-value | Yes  | No | P-value | Unemployed | HCW | Other   | P-value |
| Fatigue          |                 |                               |                   |              |          |                   |              |              |            |      |         |         |
| No               | 3 (4.2%)        | 18 (10.8%)                    | 0.132            | 3 (7.3%)     | 18 (9.1%) | 0.007           | 2 (8.7%)     | 19 (8.8%)   | 0.169      | 1 (10.0%) | 20 (8.7%) | 0.984 |
| 0-4 weeks        | 41 (56.9%)      | 74 (44.3%)                    |                   | 17 (41.5%)   | 98 (49.5%) | 8 (34.8%)       | 107 (49.5%)  |              |            | 5 (50.0%) | 110 (48.0%) | 27 (38.0%) |
| 4-12 weeks       | 14 (19.4%)      | 46 (27.5%)                    | 0.984            | 6 (14.6%)    | 54 (27.3%) | 5 (21.7%)       | 55 (25.5%)   |              |            | 2 (20.0%) | 58 (25.3%) | 20 (28.2%) |
| >12 weeks        |                 |                               |                   | 14 (19.4%)   | 29 (17.4%) | 8 (31.8%)       | 35 (16.2%)   |              |            | 2 (20.0%) | 41 (17.9%) | 17 (23.9%) |
| Headache         | No              | 30 (41.7%)                    | 0.461            | 8 (19.5%)    | 82 (41.4%) | 0.059           | 9 (39.1%)    | 81 (37.5%)  | 0.459      | 3 (30.0%) | 87 (38.0%) | 0.339 |
| 0-4 weeks        | 29 (40.3%)      | 79 (47.3%)                    |                   | 23 (56.1%)   | 85 (42.9%) | 8 (34.8%)       | 100 (46.3%)  |              |            | 4 (40.0%) | 164 (45.4%) | 42 (59.2%) |
| 4-12 weeks       | 10 (13.9%)      | 16 (9.6%)                      |                   | 7 (17.1%)    | 19 (9.6%)  | 3 (13.0%)       | 23 (10.6%)   |              |            | 1 (10.0%) | 25 (10.9%) | 8 (11.3%) |
| >12 weeks        |                 | 3 (4.2%)                      |                   | 3 (7.3%)     | 12 (6.1%)  | 2 (20.0%)       | 12 (13.0%)   |              |            | 2 (20.0%) | 13 (5.7%)  | 5 (7.0%) |
| Arthralgia       | No              | 26 (36.1%)                    | 0.163            | 16 (39.0%)   | 76 (38.4%) | 0.186           | 9 (39.1%)    | 83 (38.4%)  | 0.009      | 5 (50.0%) | 87 (38.0%) | 0.491 |
| 0-4 weeks        | 37 (51.4%)      | 64 (38.3%)                    |                   | 13 (31.7%)   | 88 (44.4%) | 5 (21.7%)       | 96 (44.4%)   |              |            | 2 (20.0%) | 99 (43.2%) | 26 (36.6%) |
| 4-12 weeks       | 5 (6.9%)        | 15 (9.0%)                      |                   | 4 (9.8%)     | 16 (8.1%)  | 2 (8.7%)        | 18 (8.3%)    |              |            | 1 (10.0%) | 19 (8.3%)  | 6 (8.5%) |
| >12 weeks        |                 | 4 (5.6%)                      |                   | 8 (19.5%)    | 18 (9.1%)  | 2 (20.0%)       | 19 (8.8%)    |              |            | 2 (20.0%) | 24 (10.5%) | 14 (19.7%) |
| Myalgia          | No              | 13 (18.1%)                    | 0.326            | 6 (14.6%)    | 41 (20.7%) | 0.007           | 6 (26.1%)    | 41 (19.0%)  | 0.066      | 3 (30.0%) | 44 (19.2%) | 0.052 |
| 0-4 weeks        | 48 (66.7%)      | 92 (55.1%)                    |                   | 21 (51.2%)   | 119 (60.1%)| 9 (39.1%)       | 131 (60.6%)  |              |            | 2 (20.0%) | 138 (60.3%) | 38 (53.5%) |
| 4-12 weeks       | 6 (8.3%)        | 19 (11.4%)                    |                   | 3 (7.3%)     | 22 (11.1%) | 2 (8.7%)        | 23 (10.6%)   |              |            | 3 (30.0%) | 22 (9.6%)  | 9 (12.7%) |
| >12 weeks        | 5 (6.9%)        | 22 (13.2%)                    |                   | 11 (26.8%)   | 16 (8.1%)  | 6 (26.1%)       | 21 (9.7%)    |              |            | 2 (20.0%) | 25 (10.9%) | 9 (12.7%) |
| Neck pain        | No              | 52 (72.2%)                    | 0.591            | 22 (53.7%)   | 143 (72.2%)| 0.009           | 18 (78.3%)   | 147 (68.1%) | 0.270      | 8 (80.0%) | 157 (68.6%) | 0.755 |
| 0-4 weeks        | 14 (19.4%)      | 30 (18.0%)                    |                   | 8 (19.5%)    | 36 (18.2%) | 2 (8.7%)        | 42 (19.4%)   |              |            | 1 (10.0%) | 43 (18.8%) | 14 (19.7%) |
| 4-12 weeks       | 3 (4.2%)        | 9 (5.4%)                      |                   | 3 (7.3%)     | 9 (4.5%)   | 0 (0.0%)        | 12 (5.6%)    |              |            | 0 (0.0%)  | 12 (5.2%)  | 2 (2.8%) |
| >12 weeks        |                 | 3 (4.2%)                      |                   | 8 (19.5%)    | 10 (5.1%)  | 3 (13.0%)       | 15 (6.9%)    |              |            | 1 (10.0%) | 17 (7.4%)  | 9 (12.7%) |
| Back pain        | No              | 43 (59.7%)                    | 0.704            | 19 (46.3%)   | 115 (58.1%)| 0.319           | 14 (60.9%)   | 120 (55.6%) | 0.769      | 9 (90.0%) | 125 (54.6%) | 0.126 |
| 0-4 weeks        | 19 (26.4%)      | 43 (25.7%)                    |                   | 11 (26.8%)   | 51 (25.8%) | 4 (17.4%)       | 58 (26.9%)   |              |            | 0 (0.0%)  | 62 (27.1%) | 20 (28.2%) |
| 4-12 weeks       | 6 (8.3%)        | 17 (10.2%)                    |                   | 5 (12.2%)    | 18 (9.1%)  | 3 (13.0%)       | 20 (9.3%)    |              |            | 1 (10.0%) | 22 (9.6%)  | 4 (5.6%) |
| >12 weeks        | 4 (5.6%)        | 16 (9.6%)                     |                   | 6 (14.6%)    | 14 (7.1%)  | 2 (8.7%)        | 18 (8.3%)    |              |            | 0 (0.0%)  | 20 (8.7%)  | 9 (12.7%) |
| Low Back pain    | No              | 37 (51.4%)                    | 0.257            | 16 (39.0%)   | 103 (52.0%)| 0.094           | 10 (43.5%)   | 109 (50.5%) | 0.262      | 4 (40.0%) | 115 (50.2%) | 0.020 |

(continued on next page)
Table 2 (continued)

| Symptom          | Gender | Presence of underlying disease | Hospitalization | ICU admission | Occupation |
|------------------|--------|--------------------------------|-----------------|--------------|------------|
|                  | Male   | Female | P-value | Yes | No | P-value | Yes | No | P-value | Yes | No | P-value | Yes | No | P-value |
| 0–4 weeks        | 27 (37.5%) | 53 (31.7%) |         | 14 (34.0%) | 66 (33.3%) | 6 (26.1%) | 74 (34.3%) | 1 (10.0%) | 79 (34.5%) | 28 (39.4%) | 12 (26.1%) | 40 (32.8%) |
| 4–12 weeks       | 6 (8.3%) | 15 (9.0%) | 0.599   | 7 (17.1%) | 12 (6.1%) | 4 (17.4%) | 15 (6.9%) | 3 (30.0%) | 16 (7.0%) | 9 (12.7%) | 2 (4.3%) | 8 (6.6%) |
| >12 weeks        | 2 (2.8%) | 17 (10.2%) |         | 7 (17.1%) | 12 (6.1%) | 4 (17.4%) | 15 (6.9%) | 3 (30.0%) | 16 (7.0%) | 9 (12.7%) | 2 (4.3%) | 8 (6.6%) |
| Hip pain         | No     | 55 (76.4%) | 130 (77.8%) | 0.599 | 29 (70.7%) | 156 (78.8%) | 0.434 | 15 (65.2%) | 170 (78.7%) | 0.001 | 9 (90.0%) | 176 (76.9%) | 0.464 | 47 (66.2%) | 38 (82.6%) | 100 (82.2%) |
| 0–4 weeks        | 12 (18.1%) | 22 (12.4%) |         | 7 (17.1%) | 28 (14.1%) | 3 (13.0%) | 32 (14.8%) | 0 (0.0%) | 7 (3.2%) | 0 (0.0%) | 7 (3.1%) | 3 (4.2%) | 1 (2.2%) | 3 (2.5%) |
| 4–12 weeks       | 2 (2.8%) | 5 (3.0%) |         | 1 (2.4%) | 6 (3.0%) | 0 (0.0%) | 7 (3.2%) | 0 (0.0%) | 7 (3.1%) | 3 (4.2%) | 1 (2.2%) | 3 (2.5%) |
| >12 weeks        | 2 (2.8%) | 10 (6.0%) |         | 4 (9.8%) | 8 (4.0%) | 5 (21.7%) | 7 (3.2%) | 1 (10.0%) | 11 (4.8%) | 8 (11.3%) | 1 (2.2%) | 3 (2.5%) |
| Leg pain         | No     | 35 (48.6%) | 63 (37.7%) | 0.599 | 10 (24.4%) | 88 (44.4%) | 0.085 | 9 (39.1%) | 89 (41.2%) | 0.141 | 5 (50.0%) | 93 (40.6%) | 0.296 | 24 (33.8%) | 17 (37.0%) | 57 (46.7%) |
| 0–4 weeks        | 25 (34.7%) | 62 (37.1%) |         | 17 (41.5%) | 70 (35.4%) | 5 (21.7%) | 82 (38.0%) | 1 (10.0%) | 86 (37.6%) | 26 (36.6%) | 19 (41.3%) | 4 (34.4%) |
| 4–12 weeks       | 7 (9.7%) | 17 (10.2%) |         | 6 (14.6%) | 18 (9.1%) | 3 (13.0%) | 21 (9.7%) | 2 (20.0%) | 22 (9.6%) | 6 (8.5%) | 6 (13.0%) | 12 (9.8%) |
| >12 weeks        | 5 (6.9%) | 25 (15.0%) |         | 8 (19.5%) | 22 (11.1%) | 6 (26.1%) | 24 (11.1%) | 2 (20.0%) | 28 (12.2%) | 15 (21.1%) | 4 (8.7%) | 11 (9.0%) |
| Chest pain       | No     | 38 (52.8%) | 105 (62.9%) | 0.599 | 19 (46.3%) | 124 (62.6%) | 0.176 | 11 (47.8%) | 132 (61.1%) | 0.058 | 6 (60.0%) | 137 (59.8%) | 0.279 | 36 (50.7%) | 30 (65.2%) | 77 (63.1%) |
| 0–4 weeks        | 21 (29.2%) | 45 (26.9%) |         | 17 (41.5%) | 49 (24.7%) | 5 (21.7%) | 61 (28.2%) | 1 (10.0%) | 65 (28.4%) | 24 (33.8%) | 11 (23.9%) | 31 (25.4%) |
| 4–12 weeks       | 6 (8.3%) | 12 (7.2%) |         | 3 (7.3%) | 15 (7.5%) | 4 (17.4%) | 14 (6.5%) | 2 (20.0%) | 16 (7.0%) | 8 (11.3%) | 8 (8.7%) | 6 (4.9%) |
| >12 weeks        | 7 (9.7%) | 5 (3.0%) |         | 2 (4.9%) | 10 (5.1%) | 3 (13.0%) | 9 (4.2%) | 1 (10.0%) | 11 (4.8%) | 3 (4.2%) | 1 (2.2%) | 8 (6.6%) |
| Bedridden due to fatigue | No | 41 (56.9%) | 97 (58.1%) | 0.070 | 20 (48.8%) | 118 (59.6%) | 0.102 | 13 (31.0%) | 135 (62.5%) | 0.001> | 2 (50.0%) | 138 (60.3%) | 0.001> | 36 (50.7%) | 26 (56.5%) | 76 (62.3%) |
| 0–4 weeks        | 28 (38.9%) | 46 (27.5%) |         | 13 (31.7%) | 61 (30.8%) | 13 (56.5%) | 61 (28.2%) | 6 (60.0%) | 68 (29.7%) | 23 (32.4%) | 16 (34.8%) | 35 (28.7%) |
| 4–12 weeks       | 2 (2.8%) | 10 (6.0%) |         | 2 (4.9%) | 10 (5.1%) | 3 (13.0%) | 9 (4.2%) | 1 (10.0%) | 11 (4.8%) | 4 (5.6%) | 2 (4.3%) | 6 (4.9%) |
| >12 weeks        | 1 (1.4%) | 14 (8.4%) |         | 6 (14.6%) | 9 (4.5%) | 4 (17.4%) | 11 (5.1%) | 3 (30.0%) | 12 (5.2%) | 8 (11.3%) | 2 (4.3%) | 5 (4.1%) |
| Bedridden due to pain | No | 61 (84.7%) | 114 (68.3%) | 0.037 | 29 (70.7%) | 146 (73.7%) | 0.097 | 13 (56.5%) | 162 (75.0%) | 0.024 | 5 (50.0%) | 170 (74.2%) | 0.003> | 41 (57.7%) | 36 (78.3%) | 98 (80.3%) |
| 0–4 weeks        | 10 (13.9%) | 37 (22.2%) |         | 7 (17.1%) | 40 (20.2%) | 5 (21.7%) | 42 (19.4%) | 2 (20.0%) | 45 (19.7%) | 20 (28.2%) | 8 (17.4%) | 19 (15.6%) |
| 4–12 weeks       | 0 (0.0%) | 5 (3.0%) |         | 0 (0.0%) | 5 (2.5%) | 1 (4.3%) | 4 (1.9%) | 0 (0.0%) | 5 (2.2%) | 2 (2.8%) | 1 (2.2%) | 2 (1.6%) |
| >12 weeks        | 1 (1.4%) | 11 (6.6%) |         | 5 (12.2%) | 7 (3.5%) | 4 (17.4%) | 8 (3.7%) | 3 (30.0%) | 9 (3.9%) | 8 (11.3%) | 1 (2.2%) | 3 (2.5%) | (continued on next page)
was associated with a higher risk of being bedridden due to pain ($P = 0.037$).

Patients who were bedridden due to fatigue were significantly older, had higher BMIs, and had lost more days due to COVID-19 than those who were not ($P < 0.05$). BMI and lost days due to COVID-19 were significantly higher in patients who had experienced shortness of breath at rest, chest pain, arthralgia, and myalgia for longer periods ($P < 0.05$).

## 4. Discussion

Studies have estimated that 10% of COVID-19 patients may continue feeling the symptoms even after the acute phase, referred to as long-COVID [4]. Many studies on patients with COVID-19 have evaluated its manifestations, including musculoskeletal symptoms, but to the best of our knowledge, no study has explicitly worked on musculoskeletal discomforts in Iran, focusing on the post-acute phase. The current study evaluated the prevalence of post-COVID musculoskeletal symptoms and associated factors. We found that BMI, gender, hospitalization due to COVID-19, and intubation are associated with a higher risk of lasting musculoskeletal symptoms in patients with COVID-19.

In our study, fatigue (91.2%), myalgia (80.3%), and headache (62.3%) were the most common symptoms. The high prevalence of fatigue in our study is consistent with the high rate of fatigue reported in previous studies, estimated to be 30–72% [12, 23]. Almost all studies on COVID-19 symptoms and limited studies on long-COVID symptoms have shown that fatigue is the most common symptom in these patients [23, 26, 27]. However, the exact etiology of fatigue is unknown. Neurotransmitter level alterations, inflammation and cytokine release, stress-induced hormones such as Cortisol, substrate metabolism, and even psychological distress are the potential contributing factors [28].

Due to various factors involved in causing fatigue, it is one common and persistent symptom in acute and chronic phases of COVID-19, which should be considered for long-term management of symptoms. It gets more critical considering that fatigue is associated with more days lost among our participants, which can increase the burden of the disease.

The most important factor associated with a longer period of musculoskeletal symptoms in our study was higher BMI, associated with arthralgia, myalgia, chest pain, bedridden due to fatigue, and exertional dyspnea. This finding is consistent with Karaarslan et al. study as they found that higher BMI is associated with a higher risk of lasting musculoskeletal symptoms in patients with COVID-19 [23]. They evaluated fatigue, myalgia, arthralgia, back pain, low back pain, and neck pain among 300 COVID-19 patients one month after discharge from the hospital and found that persistence of fatigue, myalgia, and arthralgia was related to higher BMIs [23]. BMI is a modifiable factor associated with a higher risk of long-COVID musculoskeletal symptoms, and it can be targeted in interventions to decrease the incidence of long COVID musculoskeletal symptoms. It gets more important as physical activity levels have reduced during the COVID-19 pandemic, leading to overweight and obesity among populations [29]. Designing interventions specified for the pandemic situation to improve the physical activity levels and enhance the healthy lifestyles among populations during the pandemic may be beneficial in helping people keep their BMI levels at normal levels and reducing the burden of long COVID [30]. Improvement of physical activity levels may also have additional benefits considering its role in alleviating musculoskeletal symptoms [31, 32].

In our study, hospitalization due to COVID-19 was associated with bedridden, arthralgia, and exertional dyspnea. ICU admission was also associated with bedridden and back pain. In another similar study, with a mean 110.9 days follow-up after the hospital admission of COVID-19 patients, 55.0% reported fatigue as the most common symptom. Also, most patients who were hospitalized had persistent symptoms [27]. Carvalho-Schneider et al. followed non-critical COVID-19 patients for two months and found that persistent symptoms until day 30 were associated with hospital admission and clinical dyspnea and older ages but were not associated with underlying disease [33].
Table 3. Associations between musculoskeletal symptoms and age, BMI, and lost days due to COVID-19.

| Symptom                  | Age (year) | BMI (kg/m²) | Lost days due to COVID-19 |
|--------------------------|------------|-------------|---------------------------|
|                          | Mean       | SD          | P-value                   | Mean       | SD          | P-value                   | Mean       | SD          | P-value                   |
|                          |            |             |                           |            |             |                           |            |             |                           |
| **Fatigue**              |            |             |                           |            |             |                           |            |             |                           |
| 0–4 weeks                | 34.00      | 11.84       | 0.071                     | 25.463     | 4.87        | 0.112                     | 17.94      | 18.31       | 0.016                     |
| >12 weeks                | 41.70      | 10.52       |                           | 31.075     | 21.29       |                           | 21.32      | 19.24       |                           |
| **Headache**             |            |             |                           |            |             |                           |            |             |                           |
| 0–4 weeks                | 37.67      | 11.38       | 0.271                     | 29.031     | 18.68       | 0.681                     | 18.24      | 12.11       | 0.076                     |
| >12 weeks                | 42.64      | 12.47       |                           | 26.939     | 3.20        |                           | 21.76      | 10.79       |                           |
| **Arthralgia**           |            |             |                           |            |             |                           |            |             |                           |
| 0–4 weeks                | 37.40      | 11.55       | 0.224                     | 39.908     | 36.12       |                           | 26.92      | 29.96       |                           |
| >12 weeks                | 41.50      | 9.91        |                           | 35.908     | 26.12       |                           | 26.70      | 26.28       |                           |
| **Myalgia**              |            |             |                           |            |             |                           |            |             |                           |
| 0–4 weeks                | 37.83      | 12.3        | 0.276                     | 25.111     | 4.13        |                           | 19.43      | 14.58       | 0.028                     |
| >12 weeks                | 42.69      | 12.1        |                           | 28.457     | 4.14        |                           | 29.38      | 26.19       |                           |
| **Neck pain**            |            |             |                           |            |             |                           |            |             |                           |
| 0–4 weeks                | 37.99      | 10.77       | 0.112                     | 31.161     | 25.79       | 0.379                     | 17.31      | 11.85       | 0.505                     |
| >12 weeks                | 43.67      | 10.54       |                           | 27.937     | 3.08        |                           | 27.36      | 29.19       |                           |
| **Back pain**            |            |             |                           |            |             |                           |            |             |                           |
| 0–4 weeks                | 38.07      | 11.64       | 0.959                     | 31.459     | 27.73       | 0.697                     | 17.36      | 13.04       | 0.054                     |
| >12 weeks                | 39.40      | 10.74       |                           | 27.926     | 3.73        |                           | 26.12      | 26.49       |                           |
| **Low back pain**        |            |             |                           |            |             |                           |            |             |                           |
| 0–4 weeks                | 38.03      | 11.50       | 0.367                     | 31.777     | 29.14       | 0.341                     | 19.39      | 16.73       | 0.819                     |
| >12 weeks                | 40.94      | 10.73       |                           | 28.224     | 3.25        |                           | 18.13      | 11.22       |                           |
| **Hip pain**             |            |             |                           |            |             |                           |            |             |                           |
| 0–4 weeks                | 37.73      | 11.02       | 0.560                     | 29.954     | 23.73       | 0.262                     | 18.15      | 14.37       | 0.885                     |
| >12 weeks                | 42.25      | 11.73       |                           | 28.857     | 3.59        |                           | 19.38      | 11.53       |                           |
| **Chest pain**           |            |             |                           |            |             |                           |            |             |                           |
| 0–4 weeks                | 37.59      | 10.93       | 0.422                     | 28.605     | 20.97       | 0.016                     | 17.18      | 14.56       | 0.036                     |
| >12 weeks                | 44.07      | 10.49       |                           | 33.974     | 27.02       |                           | 25.83      | 26.54       |                           |
| **Bedridden due to fatigue** |            |             |                           |            |             |                           |            |             |                           |
| 0–4 weeks                | 35.95      | 9.93        | 0.035                     | 27.640     | 15.32       | 0.003                     | 16.67      | 11.28       | 0.063                     |
| >12 weeks                | 40.18      | 10.85       |                           | 34.545     | 32.24       |                           | 18.13      | 9.62        |                           |
| **Bedridden due to pain** |            |             |                           |            |             |                           |            |             |                           |
| 0–4 weeks                | 37.85      | 10.76       | 0.097                     | 28.732     | 17.20       | 0.143                     | 17.62      | 11.90       | 0.830                     |
| >12 weeks                | 45.55      | 11.28       |                           | 30.054     | 4.95        |                           | 32.57      | 42.43       |                           |
| **Shortness of breath in rest** |            |             |                           |            |             |                           |            |             |                           |
| 0–4 weeks                | 36.54      | 10.44       | 0.092                     | 27.95      | 16.82       | 0.006                     | 14.80      | 9.99        | 0.002                     |
| >12 weeks                | 40.25      | 9.54        |                           | 29.120     | 4.56        |                           | 19.54      | 12.65       |                           |
| **Exertional dyspnea**   |            |             |                           |            |             |                           |            |             |                           |
| 0–4 weeks                | 37.44      | 11.58       | 0.055                     | 29.917     | 23.76       | 0.156                     | 15.60      | 9.90        | 0.004                     |
| >12 weeks                | 35.17      | 6.97        |                           | 27.059     | 2.97        |                           | 28.00      | 11.64       |                           |

Statistically significant values are bolded.
history indicates a more severe disease and causes a higher period of immobility, leading to longer-lasting symptoms. A higher prevalence of musculoskeletal symptoms in hospitalized patients suggests a need for rehabilitation programs for these patients to facilitate restoring their physical capacity in these patients [34].

4.1. Limitations

There are several limitations of this study worth mentioning. First, few patients in our study had been admitted to ICU or had been intubated. Due to the small sample size, our study may not have the appropriate power to evaluate their associations with musculoskeletal symptoms. Second, our study had a cross-sectional design, and we could not evaluate causal relationships. Third, the interval between the onset of COVID-19 symptoms and our study varied from one month to more than three months among participants, which is another limitation of this study as the length of follow-ups was not equal for all patients. Fourth, recall bias is another limitation of this study. Finally, about 70% of our participants were females, which should be considered in the interpretation of our findings considering the biological differences between males and females in pain perception, especially the lower threshold of females in pain perception [35].

5. Conclusion

This study indicated a high prevalence of persistent musculoskeletal symptoms among patients who recovered from COVID-19. These musculoskeletal symptoms may reduce people’s function and productivity, increasing the burden of COVID-19. Modifiable factors, such as BMI, can be targeted to reduce the prevalence of musculoskeletal symptoms in COVID-19 survivors and reduce its burden. Also, cohort studies may be beneficial for further evaluating the association between COVID-19 and persistent musculoskeletal symptoms.

Declarations

Author contribution statement

Mohaddes Azadvari: Conceived and designed the experiments; Performed the experiments; Contributed reagents, materials, analysis tools or data; Wrote the paper.

Afarin Haghparast; Amin Nakhostin-Ansari: Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data; Wrote the paper.

Seyede Zahra Emami Razavi; Maryam Hosseini: Conceived and designed the experiments; Contributed reagents, materials, analysis tools or data; Wrote the paper.

Funding statement

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Data availability statement

Data will be made available on request.

Declaration of interests statement

The authors declare no conflict of interest.

Additional information

No additional information is available for this paper.

References

[1] R. Horton, Offline: COVID-19 is not a pandemic, Lancet 396 (10255) (2020) 874.
[2] F. Jiang, L. Deng, L. Zhang, Y. Wu, C.W. Chen, Y. Cai, Review of the clinical characteristics of coronavirus disease 2019 (COVID-19), J. Gen. Intern. Med. 35 (5) (2020) 1545–1549.
[3] A. Siso-Almirall, P. Brito-Zerón, L.C. Ferrín, et al., Long covid-19: proposed primary care clinical guidelines for diagnosis and disease management, Int. J. Environ. Res. Publ. Health 18 (8) (2021).
[4] Siyuam Yang, Mingxi Hua, Xinzhe Liu, Chunjing Ju, Lin Pu, Pan Xiang, Linghong Wang, Jieyyuan Liu, Sincé January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID, Ann. Oncol. (2020).
[5] C. Chen, S.R. Haupert, L. Zimmermann, X. Shi, L.G. Fricke, B. Mukherjee, Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review, J. Infect. Dis. (April 2022).
[6] D.L. Sykes, L. Holdsworth, N. Jawad, P. Gunasekera, A.H. Morice, M.G. Crooks, Post-COVID-19 symptom burden: what is long-COVID and how should we manage it?, Lang 199 (2) (2021) 113–119.
[7] M. Mendelsohn, J. Nel, I. Blumberg, et al., Long-COVID: an evolving problem with an extensive impact, S. Afr. Med. J. 111 (1) (2020) 10–12.
[8] I. Al-Jubhalmi, K. Al-Naaman, A. Al-Mawlai, The post-acute COVID-19 syndrome (long-COVID), Oman Med. J. 36 (1) (2021) e220.
[9] H. Crook, S. Raza, J. Nowell, M. Young, E. Lidon, covid—mechanisms, risk factors, and management, BMJ (2021) 374.
[10] S.J. Yong, Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments, Inf. Disp. 53 (10) (2021) 737–754.
[11] C. Fernández-De-las-penas, D. Palacios-Cena, V. Gómez-Mayordomo, M.L. Cuadrado, L.I. Florencio, Defining post-covid symptoms (Post-covid, long covid, persistent post-covid): an integrative classification, Int. J. Environ. Res. Publ. Health 16 (5) (2021) 1–9.
[12] E. Korompoki, M. Gavriatopoulou, R.S. Hicklen, et al., Epidemiology and organ specific sequelae of post-acute COVID19: a Narrative Review, J. Infect. (2021).
[13] A. Iqbal, K. Iqbal, S. Arshad Ali, et al., The COVID-19 sequelae: a cross-sectional evaluation of post-recovery symptoms and the need for rehabilitation of COVID-19 survivors, Cureus 2 (2) (2021).
[14] M. Kamal, M. Abo Omriah, A. Hussein, H. Saeed, Assessment and characterisation of post-COVID-19 manifestations, Int. J. Clin. Pract. (2020), e13746.
[15] S. López-León, T. Wegman-Otrosky, C. Perezman, et al., More than 50 long-term effects of COVID-19: a systematic review and meta-analysis, Res Sq. (2021).
[16] A.L. Cabrera Martimbianco, R.L. Pacheco, A.L. Komaroff, L. Bateman, Will COVID-19 lead to myalgic encephalomyelitis/long covid, persistent post-covid): an integrative review, Int. J. Clin. Pract. (2021), e13557.
[17] O.L. Aiyegbusi, S.E. Hughes, G. Turner, et al., Symptoms, complications and management of long COVID: a review, J. R. Soc. Med. 114 (9) (2021) 428–442.
[18] N.P. Disser, A.J. De Michelle, M.M. Schonk, et al., Musculoskeletal sequelae of COVID-19, J. Bone Joint Surg. Am 102 (14) (2020) 1197–1204.
[19] S. SeyediAllagh, A.M. Afsahi, M. MohseniPour, et al., Late complications of COVID-19: a systematic review of current evidence, Arch. Acad. Emerg. Med. 9 (1) (2021) e14.
[20] E.B. Batur, M.K. Koreva, L.A. Goez, F. Levendoglu, O. Ural, Musculoskeletal symptoms and relationship with laboratory findings in patients with COVID-19, Int. J. Clin. Pract. 75 (6) (2021) 1–7.
[21] C.W.S. Hoong, M.N.M.E. Amin, T.C. Tan, J.E. Lee, Viral arthralgia a new characteristic of coronavirus COVID-, Ann. Oncol. (2020).
[22] S. SeyedAlinaghi, A.M. Afsahi, M. MohssenPour, et al., Late complications of COVID-19: a systematic review of current evidence, Arch. Acad. Emerg. Med. 9 (1) (2021) 1–7.
[23] S.J. Halpin, C. Mcivor, G. Whyatt, et al., Postdischarge symptoms and rehabilitation of COVID-19 patients, Cureus 8 (1) (2021) 1–8.
[24] M.A. Prieto, O. Prieto, H.M. Castro, [Long covid: cross sectional study], Rev. Fac. Cien. Med. Univ. Nac Cordoba 78 (1) (2021) 33–45.
[25] S. SeyedAllagh, A.M. Afsahi, M. MohssenPour, et al., Late complications of COVID-19: a systematic review of current evidence, Arch. Acad. Emerg. Med. 9 (1) (2021) e14.
[26] E.B. Batur, M.K. Koreva, L.A. Goez, F. Levendoglu, O. Ural, Musculoskeletal symptoms and relationship with laboratory findings in patients with COVID-19, Int. J. Clin. Pract. 75 (6) (2021) 1–7.
[27] C.W.S. Hoong, M.N.M.E. Amin, T.C. Tan, J.E. Lee, Viral arthralgia a new characteristic of coronavirus COVID-, Ann. Oncol. (2020).
[28] S. Bliddal, K. Banasik, O.B. Pedersen, et al., Acute and persistent symptoms in non-COVID-19 hospitalized patients suggests a need for rehabilitation programs for these patients to facilitate restoring their physical capacity in these patients [34].

Additional information

No additional information is available for this paper.
[33] C. Carvalho-Schneider, E. Laurent, A. Lemaignen, et al., Follow-up of adults with noncritical COVID-19 two months after symptom onset, Clin. Microbiol. Infect. 27 (2) (2021) 258–263.

[34] A. Demeco, N. Marotta, M. Barletta, et al., Rehabilitation of patients post-COVID-19 infection: a literature review, journals.sagepub.com. 48 (8) (2020).

[35] A. Soetanto, JC-J of N, Are there gender differences in pain perception?. search.proquest.com, 2006. (Accessed 8 May 2022). https://search.proquest.com/openview/de95b44222764f3510e455642/7?pg-origsite=gscholar&cbl=48278&casa_token=ZeC6a_awWGU/AAAAfpmQL77dyqAYwVPGd9yL1kSYz2FK8aPM0LeOWqikT789j1V_zSmhhlKnK3qTGW9jK2afjJQ.